Cytotoxic cis-ruthenium(III) bis(amidine) complexes

Dalton Trans. 2023 Jun 27;52(25):8540-8548. doi: 10.1039/d3dt00328k.

Abstract

In chemotherapy, the search for ruthenium compounds as alternatives to platinum compounds is proposed because of their unique properties. However, the geometry effect of ruthenium complexes is sparely investigated. In this paper, we report the synthesis of a series of bis(acetylacetonato)ruthenium(III) complexes bearing two amidines (1-) in a cis configuration. These complexes are highly cytotoxic against various cancer cell lines, including a cisplatin-resistant cell line. In vitro studies suggested that the representative complex can induce cell cycle G0/G1 phase arrest, decrease the mitochondrial membrane potential, elevate the intracellular reactive oxygen species level, and cause DNA damage and caspase-mediated mitochondrial pathway apoptosis in NCI-H460 cells. In vivo, it can effectively inhibit tumor xenograft growth in nude mouse models with no body weight loss. In combination with the reported trans-bis(amidine)ruthenium(III) complexes, we found that ruthenium(III) bis(amidine) complexes could be cytotoxic in both trans and cis geometries, which is in contrast to platinum-based compounds.

MeSH terms

  • Amidines
  • Animals
  • Antineoplastic Agents* / pharmacology
  • Apoptosis
  • Cell Cycle Checkpoints
  • Cell Line, Tumor
  • Cisplatin / pharmacology
  • Coordination Complexes* / pharmacology
  • Humans
  • Mice
  • Neoplasms*
  • Ruthenium* / pharmacology

Substances

  • Ruthenium
  • Antineoplastic Agents
  • Cisplatin
  • Amidines
  • Coordination Complexes